The Shenzhen, China-based biotech plans to launch a Phase I trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IN026.

Management projects 2026 total revenue of $78 million to $83 million, including the anticipated $25 million milestone from Chiesi. Expected revenue from Chiesi is $33 million to $35 million, ...

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases ...

Some 120 million to 130 million Americans — nearly half of US adults — are believed to take an over-the-counter pain reliever ...

Black patients were less likely to receive higher doses. This may reflect inequities in health care or misconceptions among patients that higher doses are unsafe.

People who take GLP-1 medications for several years may face a higher risk of developing osteoporosis, gout, and osteomalacia, according to new research presented Monday at the an ...

CARACAS, Venezuela — American oil traders are poised to descend on Venezuela’s capital — and may soon be able to fly here direct. The Trump administration is preparing to reopen the U.S. Embassy. The ...

Which nasal decongestant is best? Whether you’re stuffed up from allergies or are dealing with the common cold, the best nasal decongestants help reduce the symptoms of a stuffy nose. These medicines ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." GOUT CASES ARE climbing, and it's become a hot topic on the clock app. If you search up #gout, there's a ...

Quick stopped 14 of 17 shots Monday after replacing Igor Shesterkin (lower body) midway through the first period of a 3-2 overtime loss to the Mammoth. It's not yet clear how serious the injury to ...

A stubbed toe, a bruised rib, or a strep-induced sore throat brings what doctors call acute pain—it has an obvious cause and goes away as soon as the issue is healed. Knowing how to treat this type of ...